StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Safinamide

HCID 131682
Neue Reaktion
Drucken

Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen

GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
133865-89-1
Standard-SMILES
C[C@H](NCc1ccc(OCc2cccc(F)c2)cc1)C(N)=O
InChIKey
NEMGRZFTLSKBAP-LBPRGKRZSA-N
Summenformel
C17H19FN2O2
Durchschnittliche Molmasse
302,34 g/mol
Monoisotopische Masse
302,14305607

Überblick

Safinamide is an amino acid amide.

Namen und Bezeichner

Bevorzugter Name
Safinamide
IUPAC
(2S)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
Englischer Name
Safinamide
Summenformel
C17H19FN2O2
Molmasse
302.34

Namen und Synonyme

Safinamide133865-89-1(2S)-2-[[4-[(3-Fluorophenyl)methoxy]phenyl]methylamino]propanamideEMD 1195686SafinamidaFce-26743EMD-119568690ENL74SIG2-(4-(3-Fluorobenzyloxy)benzylamino)propionamideDTXCID701436700DTXSID601010282safinamidum
Weitere Namen anzeigen
(4-((3-fluorobenzyl)oxy)benzyl)-L-alanineCS-484FCE 26743SAFINAMIDSalfenamideSafranamideD4-Safinamide
(2S)-2-((4-((3-fluorophenyl)methoxy)phenyl)methylamino)propanamidefbap methanesulfonateRefChem:57040N04BD03(S)-2-((4-(3-fluorobenzoxy)benzyl)amino)propanamide603-772-2(S)-2-((4-((3-Fluorobenzyl)oxy)benzyl)amino)propanamideXadago

Datenbank-Bezeichner

CAS
133865-89-1
PubChem CID
131682
DTXSID
DTXSID601010282
ChEMBL
CHEMBL396778
ChEBI
CHEBI:134718
UNII
90ENL74SIG
EC Number
603-772-2

Eigenschaften

Berechnete StruktureigenschaftenWird ergänzt

XLogP
2,2
Polarare Oberfläche (TPSA)
64,4 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
7
Schwere Atome
22
Formalladung
0
Komplexität
346

Experimentelle und physikochemische Eigenschaften

Drugs · 2 Einträge

Pharmaceuticals -> Nervous system -> Anti-parkinson drugs

Pharmaceuticals -> Listed in ZINC15

Human Drugs · 3 Einträge

Breastfeeding; Lactation; Antiparkinson Agents; Monoamine Oxidase Inhibitors;

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

Physikochemische Eigenschaften

Schmelzpunkt
208 · 208-212°
Siedepunkt
476.7 · 476.7±40.0 °C(Predicted)
Dichte
1.189 · 1.189±0.06 g/cm3(Predicted)
storage temp.
2 · under inert gas (nitrogen or Argon) at 2–8 °C
Löslichkeit
Soluble in DMSO (up to 50 mg/ml).
Aggregatzustand
solid
pka
16.03 · 16.03±0.50(Predicted)
Farbe
White

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H301 (90.5%): Toxic if swallowed [Danger Acute toxicity, oral]

P264, P264+P265, P270, P273, P280, P301+P316, P305+P354+P338, P317, P321, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 42 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Gefahrenhinweise

Regulatory InformationStatus: Active Update: 02-08-2019 https://echa.europa.eu/registration-dossier/-/registered-dossier/21292
Hazard Classes and CategoriesAcute Tox. 3 (90.5%)

Toxikologische Informationen

Hepatotoxicity · 1 Eintrag

Safinamide has been reported to cause serum enzyme elevations in a small proportion of patients treated long term, although the abnormalities were usually mild and self-limiting and were usually no more frequent than with placebo or comparator agents. Safinamide has not been implicated in cases of acute liver injury, but such instances have been reported with nonspecific MAO inhibitors.

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

hs_code
2924.29.7790
RTECS-Nr.
TX1457385

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

N04BD03

N - Nervous system

QN - Nervous system

Protein Binding88–90%
Mechanism of Action · 1 Eintrag

Safinamide is a unique molecule with multiple mechanisms of action and a very high therapeutic index. It combines potent, selective, and reversible inhibition of MAO-B with blockade of voltage-dependent Na+ and Ca2+ channels and inhibition of glutamate release. Safinamide has neuroprotective and neurorescuing effects in MPTP-treated mice, in the rat kainic acid, and in the gerbil ischemia model.

Biological Half-Life22 h
Metabolism/Metabolites · 1 Eintrag

The principal step is mediated by amidases which have not been identified, and produces safinamide acid. It is also metabolized to O-debenzylated safinamide and N-delkylated amine. The N-dealkylated amine is then oxidized to a carboxylic acid and finally glucuronidated. Dealkylation reactions are mediated by cytochrome P450s (CYPs), especially CYP3A4. Safinamide acid binds to organic anion transporter 3 (OAT3), but no clinical relevance of this interaction has been determined. Safinamide also binds to ABCG2 transiently. No other transporter affinities have been found in preliminary studies.

FDA Pharmacological Classification · 6 Einträge

90ENL74SIG

SAFINAMIDE

Established Pharmacologic Class [EPC] - Monoamine Oxidase Type B Inhibitor

Mechanisms of Action [MoA] - Monoamine Oxidase-B Inhibitors

Mechanisms of Action [MoA] - Breast Cancer Resistance Protein Inhibitors

Safinamide is a Monoamine Oxidase Type B Inhibitor. The mechanism of action of safinamide is as a Monoamine Oxidase-B Inhibitor and Breast Cancer Resistance Protein Inhibitor.

Absorption, Distribution and Excretion · 4 Einträge

Rapid with peak plasma concentrations ranging from 2 to 4 h, total bioavailability is 95%. Food prolonged the rate and did not affect the extent of absorption of safinamide.

Zugehörige Reaktionen

16
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 41736
HRID 41736als Edukt
Reaktionsgleichung von HRID 41737
HRID 41737als Edukt
Reaktionsgleichung von HRID 41738
HRID 41738als Produkt
Reaktionsgleichung von HRID 41740
HRID 41740als Produkt
Reaktionsgleichung von HRID 41741
HRID 41741als Edukt
Reaktionsgleichung von HRID 83473
HRID 83473als Edukt
Reaktionsgleichung von HRID 83474
HRID 83474als Edukt
Reaktionsgleichung von HRID 83475
HRID 83475als Produkt
ZurückSeite 1 von 2

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
Nikkaji
J621.455J
Merck
14 · 14,8315
Stabilität
2 years · Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
InChI
InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1
InChIKey
NEMGRZFTLSKBAP-LBPRGKRZSA-N
SMILES
C(N)(=O)[C@@H](NCC1=CC=C(OCC2=CC=CC(F)=C2)C=C1)C

76% renal, 1.5% faeces

1.8 litres/kg

total oral clearance of plasma , which accounts for parent safinamide as well as metabolites, was on average only 17.53 ± 2.71 ml/h × kg

Anwendungen · 1 Eintrag

HistorySafinamide is an α-aminoamide derivative with a multimodal mechanism of action involving both dopaminergic and non-dopaminergic properties. It increases levels of available dopamine through dopamine reuptake inhibition andMAO-B inhibition. It is a potent and reversible inhibitor of MAO-B, with significantly greater selectivity for MAO-B over MAO-A than selegiline and rasagiline. However, it also has an important and novel mode of action that involves blockade of Na+ channels andmodulation of Ca2+ channels that inhibits glutamate release and therefore may provide a level of cognitive improvement and neuroprotection. Homeostatic interactions between dopamine and glutamate are central to the normal physiology of the basal ganglia. In PD, this relationship is altered, resulting in upregulation of cortico-striatal glutamatergic function in l-dopa-induced dyskinesia. Any drug that can counteract such unbalance in glutamate function is potentially useful in controlling dyskinesias. Safinamide was originated by Farmitalia Carlo Erba, a company that was later purchased by Pharmacia. Newron Pharmaceuticals was established as a spin-off of Pharmacia in 1999 and acquired safinamide rights and intellectual property from Pharmacia Corporation. Newron originally granted Serono exclusive worldwide rights to develop, manufacture, and commercialize safinamide in 2006. However, in October 2011, Merck Serono agreed to return full global rights for safinamide to Newron. Newron then finalized a strategic collaboration and license agreement with Zambon for the worldwide development and commercialization of safinamide.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

L-Alaninamide(S,E)-2-((4-((3-fluorobenzyl)4-(3-fluoro-benzyloxy)-benzaldehydeL-Alaninamide hydrochlorideKaliumtetrahydroboratMethanol